Are you Dr. Yarchoan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 9 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr Msc 1868 Nih
Bldg 10
Bethesda, MD 20892Phone+1 301-496-0328Fax+1 301-480-5955
Summary
- Dr. Robert Yarchoan, MD is an allergist/immunologist in Bethesda, Maryland. He is currently licensed to practice medicine in Maryland and Minnesota.
Education & Training
Perelman School of Medicine at the University of PennsylvaniaClass of 1975
Certifications & Licensure
MD State Medical License 1978 - 2025
MN State Medical License 1976 - 2023- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1993
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Start of enrollment: 2000 Dec 06
- Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions Start of enrollment: 2001 Apr 23
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Start of enrollment: 2004 Oct 28
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsCancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Vanessa Eulo, Gaurav Goyal
Journal of Clinical Oncology. 2025-02-01 - Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.Kathryn Lurain, Ramya Ramaswami, Eric Oksenhendler, David Boutboul, Alessia Dalla Pria
American Journal of Hematology. 2025-01-15 - Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir.M Ali Rai, Jana Blazkova, Lela Kardava, Jesse S Justement, Victoria Shi
Nature Medicine. 2025-01-03
Press Mentions
HIV-Associated Cancers: A Paradigm Shift?April 19th, 2018
Grant Support
- Study Of Tumor Pathogenesis And Development Of Therapies For AIDS MalignanciesNational Cancer Institute2010–2011
- Development Of Novel Therapies For HIV InfectionNational Cancer Institute2010–2011
- Clinical Trials Of Patients With Aids-Related MalignanciesNational Cancer Institute2010–2011
- Development Of Novel Therapies For HIV InfectionDivision Of Clinical Sciences - Nci2009
- Study Of Tumor Pathogenesis And Development Of Therapies For Aids-MalignanciesDivision Of Basic Sciences - Nci2009
- Clinical Trials Of Patients With Aids-Related MalignanciesDivision Of Basic Sciences - Nci2009
- Development Of Novel Therapies For HIV InfectionNational Cancer Institute2008
- Clinical Trials Of Patients With Aids-Related MalignanciesNational Cancer Institute2008
- Pediatric Hivaids Clinical ResearchNational Cancer Institute2007–2008
- Development Of Novel Therapies For HIV Infection And Aids-Related MalignanciesNational Cancer Institute2007
- Pediatric Hivaids Clinical ResearchDivision Of Clinical Sciences - Nci2005–2006
- Development Of Novel Therapies For HIV Infection And AIDDivision Of Clinical Sciences - Nci2002–2006
- Novel Therapies For HIV Inf. &Aids-Related MalignanciesDivision Of Clinical Sciences - Nci2004
- Pediatric HIV/AIDS Clinical ResearchDivision Of Clinical Sciences - Nci1999–2004
- Development Of Novel Therapies For HIV Infection And RELDivision Of Clinical Sciences - Nci2001
- Development Of Novel Therapies For HIV Infection And Related MalignanciesDivision Of Clinical Sciences - Nci1997–2000
- Development Of Novel Therapies For HIV Infection &Related MalignanciesDivision Of Clinical Sciences - Nci1996
